MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential

World Journal of Gastroenterology

Volumn 20, Issue 38, 2014, Pages 13658-13666

  Matuszcak, Christiane ^a   Haier, Joerg ^a   Hummel, Richard ^a   Lindner, Kirsten ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Biomarker; Chemoresistance; Diagnostic; Gastric cancer; MicroRNAs; Therapeutic

Indexed keywords

MICRORNA; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESISTANCE; DISEASE COURSE; DISEASE MARKER; HUMAN; REVIEW; STOMACH CANCER; ANIMAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC SCREENING; GENETICS; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROCEDURES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GENETIC THERAPY; HUMANS; MICRORNAS; PATIENT SELECTION; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84910020172     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i38.13658     Document Type: Review

References (90)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Wilke MS. Therapie beim Magenkarzinom. Chirurg 2009; 80: 1023-1027
3. Robb WB, Mariette C. Predicting the response to chemotherapy in gastric adenocarcinoma: who benefits from neoadjuvant chemotherapy? Recent Results Cancer Res 2012; 196: 241-268 [PMID: 23129379 DOI: 10.1007/978-3-642-31629-6-17]
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]
5. Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouch O, Segol P, Bedenne L, Rougier P, Ychou M. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007; 25 Suppl: 4510
6. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721 [PMID: 21444866 DOI: 10.1200/JCO.2010.33.0597]
7. Kasper S, Schuler M. Targeted therapies in gastroesophageal cancer. Eur J Cancer 2014; 50: 1247-1258 [PMID: 24495747 DOI: 10.1016/j.ejca.2014.01.009]
8. Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buyse M, Burzykowski T. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst 2013; 105: 1600-1607 [PMID: 24108812 DOI: 10.1093/jnci/djt270]
9. Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Jensen K. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev 2013; 5: CD008107 [PMID: 23728671 DOI: 10.1002/14651858.CD008107.pub2]
10. Szakács G, Jakab K, Antal F, Sarkadi B. Diagnostics of multidrug resistance in cancer. Pathol Oncol Res 1998; 4: 251-257 [PMID: 9887354 DOI: 10.1007/BF02905214]
11. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23 [PMID: 17084534 DOI: 10.1016/j.ctrv.2006.09.006]
12. Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ. A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 2000; 38: 1-11 [PMID: 10811443]
13. Harfe BD. MicroRNAs in vertebrate development. Curr Opin Genet Dev 2005; 15: 410-415 [PMID: 15979303 DOI: 10.1016/j.gde.2005.06.012]
14. Hwang W, Hwang Y, Lee S, Lee D. Rule-based multi-scale simulation for drug effect pathway analysis. BMC Med Inform Decis Mak 2013; 13 Suppl 1: S4 [PMID: 23566173 DOI: 10.1186/1472-6947-13-S1-S4]
15. Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res 2013; 33: 1257-1266 [PMID: 23564763]
16. David S, Meltzer SJ. MicroRNA involvement in esophageal carcinogenesis. Curr Opin Pharmacol 2011; 11: 612-616 [PMID: 21992930 DOI: 10.1016/j.coph.2011.09.006]
17. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39: D152-D157 [PMID: 21037258]
18. Li L, Yang F, Wang X, Hu J, Yang L, Tang C, Wu Y, Miao K, Liu R, Shou T. Effect of 15-hydroxyprostaglandin dehydrogenase gene on the proliferation of gastric cancer cell murine forestomach carcinoma. Exp Ther Med 2014; 7: 290-294 [PMID: 24348808 DOI: 10.3892/etm.2013.1404]
19. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: profile, profile, profile. Int J Cancer 2008; 122: 969-977 [PMID: 18098138 DOI: 10.1002/ijc.23343]
20. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20 [PMID: 15652477 DOI: 10.1016/j.cell.2004.12.035]
21. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269 [PMID: 16557279 DOI: 10.1038/nrc1840]
22. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866 [PMID: 17060945 DOI: 10.1038/nrc1997]
23. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, Musolino C. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol 2012; 41: 1897-1912 [PMID: 23026890 DOI: 10.3892/ijo.2012.1647]
24. Guo LH, Li H, Wang F, Yu J, He JS. The Tumor Suppressor Roles of miR-433 and miR-127 in Gastric Cancer. Int J Mol Sci 2013; 14: 14171-14184 [PMID: 23880861 DOI: 10.3390/ijms140714171]
25. Hou Z, Xie L, Yu L, Qian X, Liu B. MicroRNA-146a is downregulated in gastric cancer and regulates cell proliferation and apoptosis. Med Oncol 2012; 29: 886-892 [PMID: 21347720 DOI: 10.1007/s12032-011-9862-7]
26. Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM, Zhang X, Jiang L, Xing CZ, Zhang Y. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer 2011; 10: 1 [PMID: 21205300 DOI: 10.1186/1476-4598-10-1]
27. Peng W, Chen ZY, Wang L, Wang Z, Li J. MicroRNA-199a-3p is downregulated in gastric carcinomas and modulates cell proliferation. Genet Mol Res 2013; 12: 3038-3047 [PMID: 24065659 DOI: 10.4238/2013.August.20.5]
28. Xiong X, Ren HZ, Li MH, Mei JH, Wen JF, Zheng CL. Down-regulated miRNA-214 induces a cell cycle G1 arrest in gastric cancer cells by up-regulating the PTEN protein. Pathol Oncol Res 2011; 17: 931-937 [PMID: 21688200 DOI: 10.1007/s12253-011-9406-7]
29. Chen G, Shen ZL, Wang L, Lv CY, Huang XE, Zhou RP. Hsa-miR-181a-5p expression and effects on cell proliferation in gastric cancer. Asian Pac J Cancer Prev 2013; 14: 3871-3875 [PMID: 23886199]
30. Xu XD, He XJ, Tao HQ, Zhang W, Wang YY, Ye ZY, Zhao ZS. Abnormal expression of miR-301a in gastric cancer associated with progression and poor prognosis. J Surg Oncol 2013; 108: 197-202 [PMID: 23832550 DOI: 10.1002/jso.23374]
31. Zhang X, Li X, Tan Z, Liu X, Yang C, Ding X, Hu X, Zhou J, Xiang S, Zhou C, Zhang J. MicroRNA-373 is upregulated and targets TNFAIP1 in human gastric cancer, contributing to tumorigenesis. Oncol Lett 2013; 6: 1427-1434 [PMID: 24179536 DOI: 10.3892/ol.2013.1534]
32. Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu L, Chen Z, Meng Z. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol 2013; 7: 334-345 [PMID: 23177026 DOI: 10.1016/j.molonc.2012.10.011]
33. Chistiakov DA, Chekhonin VP. Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential. Eur J Pharmacol 2012; 684: 8-18 [PMID: 22484336 DOI: 10.1016/j.ejphar.2012.03.031]
34. de la Chapelle A, Jazdzewski K. MicroRNAs in thyroid cancer. J Clin Endocrinol Metab 2011; 96: 3326-3336 [PMID: 21865360 DOI: 10.1210/jc.2011-1004]
35. Marcucci G, Radmacher MD, Mrózek K, Bloomfield CD. MicroRNA expression in acute myeloid leukemia. Curr Hematol Malig Rep 2009; 4: 83-88 [PMID: 20425419 DOI: 10.1007/s11899-009-0012-7]
36. Millan MJ. MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. Curr Opin Pharmacol 2011; 11: 11-22 [PMID: 21345728 DOI: 10.1016/j.coph.2011.01.008]
37. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110: 483-495 [PMID: 22302755 DOI: 10.1161/CIRCRESAHA.111.247452]
38. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
39. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159 [PMID: 22351564 DOI: 10.1002/emmm.201100209]
40. Xiao YF, Yong X, Fan YH, Lü MH, Yang SM, Hu CJ. microRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (Review). Oncol Rep 2013; 30: 535-544 [PMID: 23754129 DOI: 10.3892/or.2013.2525]
41. Fang Y, Fang D, Hu J. MicroRNA and its roles in esophageal cancer. Med Sci Monit 2012; 18: RA22-RA30 [PMID: 22367141]
42. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-1741 [PMID: 20847327 DOI: 10.1373/clinchem.2010.147405]
43. Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta 2014; 1845: 255-265 [PMID: 24569228 DOI: 10.1016/j.bbcan.2014.02.002]
44. Ma D, Tao X, Gao F, Fan C, Wu D. miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett 2012; 4: 483-488 [PMID: 23741247 DOI: 10.3892/ol.2012.742]
45. Rayner KJ, Hennessy EJ. Extracellular communication via microRNA: lipid particles have a new message. J Lipid Res 2013; 54: 1174-1181 [PMID: 23505318 DOI: 10.1194/jlr.R034991]
46. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006 [PMID: 18766170 DOI: 10.1038/cr.2008.282]
47. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101: 2087-2092 [PMID: 20624164 DOI: 10.1111/j.1349-7006.2010.01650.x]
48. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838 [PMID: 15944708 DOI: 10.1038/nature03702]
49. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-7233 [PMID: 21609964 DOI: 10.1093/nar/gkr254]
50. Turchinovich A, Burwinkel B. Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol 2012; 9: 1066-1075 [PMID: 22858679 DOI: 10.4161/rna.21083]
51. Kim T, Reitmair A. Non-Coding RNAs: Functional Aspects and Diagnostic Utility in Oncology. Int J Mol Sci 2013; 14: 4934-4968 [PMID: 23455466 DOI: 10.3390/ijms14034934]
52. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-659 [PMID: 17486113 DOI: 10.1038/ncb1596]
53. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, Baty CJ, Gibson GA, Erdos G, Wang Z, Milosevic J, Tkacheva OA, Divito SJ, Jordan R, Lyons- Weiler J, Watkins SC, Morelli AE. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012; 119: 756-766 [PMID: 22031862 DOI: 10.1182/blood-2011-02-338004]
54. Quackenbush JF, Cassidy PB, Pfeffer LM, Boucher KM, Hawkes JE, Pfeffer SR, Kopelovich L, Leachman SA. Isolation of circulating microRNAs from microvesicles found in human plasma. Methods Mol Biol 2014; 1102: 641-653 [PMID: 24259003 DOI: 10.1007/978-1-62703-727-3-34]
55. Mo MH, Chen L, Fu Y, Wang W, Fu SW. Cell-free Circulating miRNA Biomarkers in Cancer. J Cancer 2012; 3: 432-448 [PMID: 23074383 DOI: 10.7150/jca.4919]
56. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8: 467-477 [PMID: 21647195 DOI: 10.1038/nrclinonc.2011.76]
57. Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer 2010; 126: 2-10 [PMID: 19634138 DOI: 10.1002/ijc.24782]
58. Cho S, Lu M, He X, Ee PL, Bhat U, Schneider E, Miele L, Beck WT. Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci USA 2011; 108: 20778-20783 [PMID: 22143792 DOI: 10.1073/pnas.1019452108]
59. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol 2012; 13: e249-e258 [PMID: 22652233 DOI: 10.1016/S1470-2045(12)70073-6]
60. Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J, Hussey DJ. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011; 15: 429-438 [PMID: 21246413 DOI: 10.1007/s11605-011-1418-9]
61. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP. Involvement of mi-croRNA- 451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-2159 [PMID: 18645025 DOI: 10.1158/1535-7163.MCT-08-0021]
62. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372-379 [PMID: 18449891 DOI: 10.1002/ijc.23501]
63. Marin JJ, Briz O, Monte MJ, Blazquez AG, Macias RI. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr Cancer Drug Targets 2012; 12: 402-438 [PMID: 22229248 DOI: 10.1002/9780470015902.a0025217]
64. Marin JJ, Romero MR, Martinez-Becerra P, Herraez E, Briz O. Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. Curr Mol Med 2009; 9: 1108-1129 [PMID: 19747110 DOI: 10.2174/156652409789839125]
65. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292 [PMID: 15641020]
66. Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 2007; 26: 311-320 [PMID: 17504027]
67. Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 2014; 18: 371-390 [PMID: 24533657 DOI: 10.1111/jcmm.12236]
68. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez- Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-1694 [PMID: 23534542 DOI: 10.1056/NEJMoa1209026]
69. Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug. J Cell Biol 2012; 199: 407-412 [PMID: 23109665 DOI: 10.1083/jcb.201208082]
70. Hildebrandt-Eriksen ES, Bagger YZ, Knudsen TB. A unique therapy for HCV inhibits microRNA-122 in humans and results in HCV RNA suppression in chronically infected chimpanzees: results from primate and first-in-human studies. Hepatology 2009; 50 Suppl: Abstract 228
71. Zhao Y, Liang YR. [In situ hybridization study of HBV DNA in chronic active hepatitis]. Zhonghua Bing Li Xue Zazhi 1990; 19: 42-45 [PMID: 2383912 DOI: 10.1038/nbt0713-577]
72. A Multicenter Phase I Study of MRX34, MicroRNA miRRX34 Liposome Injectable Suspension. Accessed on 1 November 2013. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT01829971?term=NCT01829971&rank=1/
73. Lindner K, Haier J, Hummel R. MicroRNAs and Their Clinical Impact on Resistance to Anticancer Treatment. In: Babashah S. MicroRNAs: Key Regulators of Oncogenesis. 2014 edition. Heidelberg: Springer, 2014: 369-386
74. Collins S. Oncology Biomarker Diagnostics: Where We Are, Where We Need To Be: Identifying cancer biomarkers that are clinically useful is difficult. So is obtaining funding to get biomarker diagnostics to market. Biotechnol Healthc 2010; 7: 22-25 [PMID: 22478826]
75. Bhatt AN, Mathur R, Farooque A, Verma A, Dwarakanath BS. Cancer biomarkers - current perspectives. Indian J Med Res 2010; 132: 129-149 [PMID: 20716813]
76. Mäbert K, Cojoc M, Peitzsch C, Kurth I, Souchelnytskyi S, Dubrovska A. Cancer biomarker discovery: current status and future perspectives. Int J Radiat Biol 2014; 90: 659-677 [PMID: 24524284 DOI: 10.3109/09553002.2014.892229]
77. Wang F, Li T, Zhang B, Li H, Wu Q, Yang L, Nie Y, Wu K, Shi Y, Fan D. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013; 434: 688-694 [PMID: 23603256 DOI: 10.1016/j.bbrc.2013.04.010]
78. Yang SM, Huang C, Li XF, Yu MZ, He Y, Li J. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology 2013; 306: 162-168 [PMID: 23466500 DOI: 10.1016/j.tox.2013.02.014]
79. Fang Y, Shen H, Li H, Cao Y, Qin R, Long L, Zhu X, Xie C, Xu W. miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai) 2013; 45: 963-972 [PMID: 24108762 DOI: 10.1093/abbs/gmt106]
80. Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, Yu X, Xia T, Cui L, Guo J. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 2013; 518: 351-359 [PMID: 23333942 DOI: 10.1016/j.gene.2012.12.103]
81. Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K, Zhou L, Sun Y, Li M, Zhou J, An Y, Wu K, Nie Y, Fan D. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2014; 33: 3267-3276 [PMID: 23893241 DOI: 10.1038/onc.2013.297]
82. Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010; 127: 2520-2529 [PMID: 20162574 DOI: 10.1002/ijc.25260]
83. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, Shu Y, Liu P. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012; 29: 384-391 [PMID: 21258880 DOI: 10.1007/s12032-010-9797-4]
84. Wu XM, Shao XQ, Meng XX, Zhang XN, Zhu L, Liu SX, Lin J, Xiao HS. Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011; 32: 259-269 [PMID: 21293479 DOI: 10.1038/aps.2010.204]
85. Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011; 4: 79 [PMID: 22112324 DOI: 10.1186/1755-8794-4-79]
86. Zhu X, Lv M, Wang H, Guan W. Identification of circulating microRNAs as novel potential biomarkers for gastric cancer detection: a systematic review and meta-analysis. Dig Dis Sci 2014; 59: 911-919 [PMID: 24337687 DOI: 10.1007/s10620-013-2970-9]
87. Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011; 30: 55 [PMID: 21569481 DOI: 10.1186/1756-9966-30-55]
88. Hu J, Fang Y, Cao Y, Qin R, Chen Q. miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci 2014; 59: 336-345 [PMID: 24248414 DOI: 10.1007/s10620-013-2923-3]
89. Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-Gonzalez JA, Ramirez N, Sola JJ, Jimenez P, Rodriguez J, Garcia-Foncillas J. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 2009; 15: 2281-2290 [PMID: 19318487 DOI: 10.1158/1078-0432.CCR-08-1818]
90. DIANA miRPath v2.0. Available from: URL: http://diana.imis. athena-innovation.gr/DianaTools/index.php?r=mirpath/index